Byeongzu Ghang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Byeongzu Ghang has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Bin Yoo
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
8 shared publicationsJinseok Kim
Division of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital , Jeju
7 shared publications- Yong-Gil Kim
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7 shared publications - Chang-Keun Lee
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
6 shared publications - Bin Yoo
Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 shared publications - Seokchan Hong
Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
Factors for malignancy in dermatomyositis and polymyositis: focusing on clinical and histopathologic aspects
So Hye Nam, M.D., Byeongzu Ghang, M.D., Ph.D., Jungsun Lee, M.D., Ph.D., Doo-Ho Lim, M.D., Ph.D., Soo Min Ahn, M.D., Ji Seon Oh, M.D., Ph.D., Seokchan Hong, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Soo Jeong Nam, M.D., Ph.D., Bin Yoo, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2026.0078
- 28 October 2026
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
Open AccessFactors for malignancy in dermatomyositis and polymyositis: focusing on clinical and histopathologic aspects
So Hye Nam, M.D., Byeongzu Ghang, M.D., Ph.D., Jungsun Lee, M.D., Ph.D., Doo-Ho Lim, M.D., Ph.D., Soo Min Ahn, M.D., Ji Seon Oh, M.D., Ph.D., Seokchan Hong, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Soo Jeong Nam, M.D., Ph.D., Bin Yoo, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2026.0078
- 1 October 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (6) , 393-402
Cardiovascular risk and all-cause mortality across low-density lipoprotein cholesterol levels in seropositive rheumatoid arthritis: a nationwide cohort study
- 1 October 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (6) , 393-402
Cardiovascular risk and all-cause mortality across low-density lipoprotein cholesterol levels in seropositive rheumatoid arthritis: a nationwide cohort study
- 12 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70755
Time‐Dependent Effects of Plasma Exchange in Severe ANCA ‐Associated Vasculitis: A Re‐Examination of the PEXIVAS Trial
- 12 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70755
Time‐Dependent Effects of Plasma Exchange in Severe ANCA ‐Associated Vasculitis: A Re‐Examination of the PEXIVAS Trial
- Open Access
- 21 October 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (1) , 7-18
Current and future treatment of rheumatoid arthritis
Jin Kyun Park, M.D., Ph.D., Byeongzu Ghang, M.D., Ph.D., Seung Woo Han, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0034
- 21 October 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (1) , 7-18
Open AccessCurrent and future treatment of rheumatoid arthritis
Jin Kyun Park, M.D., Ph.D., Byeongzu Ghang, M.D., Ph.D., Seung Woo Han, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0034
- 14 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Ten-year cardiovascular risk changes and major adverse events in gout patients
Objective: The long-term interaction between cardiovascular (CV) risk profiles and gout may influence the risk of cardiovascular events. However, the impact of gout and long-term changes in CV risk profile on CV events is unclear. Methods: This was a nationwide cohort study based on the Korean National Health Insurance claims database and the National Health Screening Program. Patients aged 20–90 years newly diagnosed with gout after January 2012 and age- and sex-matched controls without gout were included. After adjusting for CV risk profiles measured 10 years before gout diagnosis and their long-term changes, the relative risks of incident CV events (myocardial infarction, cerebral infarction and cerebral haemorrhage) and all-cause death in the gout patients were assessed. Results: In total, 113 853 patients with gout and 1 138 530 matched controls were studied. Multivariable analysis showed that gout was associated with increased risks for myocardial infarction (hazard ratio [HR]: 1.39, P < 0.001), cerebral infarction (HR: 1.36, P < 0.001), cerebral haemorrhage (HR: 1.50, P < 0.001), and all-cause death (HR: 1.07, P = 0.004). In addition, significant interactions were observed for myocardial infarction (Grade 1 aggravation over 10 years of diastolic blood pressure [DBP], P = 0.042), cerebral infarction (Grade 2 aggravation over 10 years of DBP, P = 0.037) and cerebral haemorrhage (Grade 2 aggravation over 10 years of total cholesterol, P = 0.057). Conclusions: Gout patients had a high risk of incident CV events even after adjusting for CV risk profiles and their long-term changes. These long-term changes additively increase the risk of CV events in gout patients.
- 14 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Ten-year cardiovascular risk changes and major adverse events in gout patients
Objective: The long-term interaction between cardiovascular (CV) risk profiles and gout may influence the risk of cardiovascular events. However, the impact of gout and long-term changes in CV risk profile on CV events is unclear. Methods: This was a nationwide cohort study based on the Korean National Health Insurance claims database and the National Health Screening Program. Patients aged 20–90 years newly diagnosed with gout after January 2012 and age- and sex-matched controls without gout were included. After adjusting for CV risk profiles measured 10 years before gout diagnosis and their long-term changes, the relative risks of incident CV events (myocardial infarction, cerebral infarction and cerebral haemorrhage) and all-cause death in the gout patients were assessed. Results: In total, 113 853 patients with gout and 1 138 530 matched controls were studied. Multivariable analysis showed that gout was associated with increased risks for myocardial infarction (hazard ratio [HR]: 1.39, P < 0.001), cerebral infarction (HR: 1.36, P < 0.001), cerebral haemorrhage (HR: 1.50, P < 0.001), and all-cause death (HR: 1.07, P = 0.004). In addition, significant interactions were observed for myocardial infarction (Grade 1 aggravation over 10 years of diastolic blood pressure [DBP], P = 0.042), cerebral infarction (Grade 2 aggravation over 10 years of DBP, P = 0.037) and cerebral haemorrhage (Grade 2 aggravation over 10 years of total cholesterol, P = 0.057). Conclusions: Gout patients had a high risk of incident CV events even after adjusting for CV risk profiles and their long-term changes. These long-term changes additively increase the risk of CV events in gout patients.
- Open Access
- 6 February 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 32 (3) , 166-181
Current state and future directions of basic research in rheumatoid arthritis
Byeongzu Ghang, M.D., Ph.D., Jin Kyun Park, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Seungwoo Han, M.D., Ph.D.. J Rheum Dis 2025;32:166-81. https://doi.org/10.4078/jrd.2024.0151
- 6 February 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 32 (3) , 166-181
Open AccessCurrent state and future directions of basic research in rheumatoid arthritis
Byeongzu Ghang, M.D., Ph.D., Jin Kyun Park, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Seungwoo Han, M.D., Ph.D.. J Rheum Dis 2025;32:166-81. https://doi.org/10.4078/jrd.2024.0151
- 15 November 2024
- Published by Elsevier in Kidney International
- Vol. 107 (3) , 521-529
Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy
- 15 November 2024
- Published by Elsevier in Kidney International
- Vol. 107 (3) , 521-529
Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy
- 1 October 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (11) , 3379-3387
Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients
Objective To identify the risk factors for relapse of idiopathic inflammatory myopathies (IIMs). Methods Patients who were newly diagnosed with IIMs and underwent muscle biopsy between 2000 and 2017 at Asan Medical Center were retrospectively reviewed. The relapse of IIMs was defined as the recurrence of muscle or cutaneous manifestations with a ≥50% increase in glucocorticoid dosage after reaching the low-dose glucocorticoid phase with clinically significant improvement. The factors associated with the relapse of IIMs were investigated by Cox proportional hazards analysis. Results Of 105 patients with IIMs, relapse was observed in 65 patients (62%). The titer of antinuclear antibody (ANA) was higher in the relapse group than in the non-relapse group (P = 0.033). Multivariable analysis showed that the relapse of IIMs was significantly associated with histopathologic features consistent with IIMs (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.01–2.83, P = 0.045) and the use of immunosuppressants before relapse (HR, 0.50; 95% CI, 0.29–0.86, P = 0.013). Doubling of ANA titer was also associated with relapse, albeit without statistical significance (HR, 1.13; 95% CI, 1.00–1.27, P = 0.052). Conclusion In patients with IIMs, the use of immunosuppressants had a significant negative association with relapse. Administering immunosuppressants from the early period during the initial glucocorticoid tapering phase may be useful in reducing the risk of relapse in patients with IIMs. Key Points • Since idiopathic inflammatory myopathies (IIMs) have a low prevalence, it is poorly understood which factors are associated with the relapse of IIMs. • In this study, about two-thirds of 105 patients with IIMs experienced a relapse of IIMs. • The risk of relapse in patients with IIMs was negatively associated with the use of immunosuppressants during glucocorticoid tapering and low-dose glucocorticoid phase. • Even in less severe cases, the use of immunosuppressants might be a good option for the management of IIMs.
- 1 October 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (11) , 3379-3387
Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients
Objective To identify the risk factors for relapse of idiopathic inflammatory myopathies (IIMs). Methods Patients who were newly diagnosed with IIMs and underwent muscle biopsy between 2000 and 2017 at Asan Medical Center were retrospectively reviewed. The relapse of IIMs was defined as the recurrence of muscle or cutaneous manifestations with a ≥50% increase in glucocorticoid dosage after reaching the low-dose glucocorticoid phase with clinically significant improvement. The factors associated with the relapse of IIMs were investigated by Cox proportional hazards analysis. Results Of 105 patients with IIMs, relapse was observed in 65 patients (62%). The titer of antinuclear antibody (ANA) was higher in the relapse group than in the non-relapse group (P = 0.033). Multivariable analysis showed that the relapse of IIMs was significantly associated with histopathologic features consistent with IIMs (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.01–2.83, P = 0.045) and the use of immunosuppressants before relapse (HR, 0.50; 95% CI, 0.29–0.86, P = 0.013). Doubling of ANA titer was also associated with relapse, albeit without statistical significance (HR, 1.13; 95% CI, 1.00–1.27, P = 0.052). Conclusion In patients with IIMs, the use of immunosuppressants had a significant negative association with relapse. Administering immunosuppressants from the early period during the initial glucocorticoid tapering phase may be useful in reducing the risk of relapse in patients with IIMs. Key Points • Since idiopathic inflammatory myopathies (IIMs) have a low prevalence, it is poorly understood which factors are associated with the relapse of IIMs. • In this study, about two-thirds of 105 patients with IIMs experienced a relapse of IIMs. • The risk of relapse in patients with IIMs was negatively associated with the use of immunosuppressants during glucocorticoid tapering and low-dose glucocorticoid phase. • Even in less severe cases, the use of immunosuppressants might be a good option for the management of IIMs.
- Open Access
- 8 June 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 30 (3) , 185-197
Regional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea
Hyun Jung Kim, Ph.D., Byeongzu Ghang, M.D., Ph.D., Jinseok Kim, M.D., Ph.D., Hyeong Sik Ahn, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0011
- 8 June 2023
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 30 (3) , 185-197
Open AccessRegional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea
Hyun Jung Kim, Ph.D., Byeongzu Ghang, M.D., Ph.D., Jinseok Kim, M.D., Ph.D., Hyeong Sik Ahn, M.D., Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2023.0011
- 2 September 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 5618-5620
Autoimmune rheumatic disease after SARS‐CoV‐2 vaccination
- 2 September 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (12) , 5618-5620
Autoimmune rheumatic disease after SARS‐CoV‐2 vaccination